Mastocytoma: topical corticosteroid treatment

Mateo, J. Redondo

doi:10.1046/j.1468-3083.2001.t01-3-00340.x

Cited by 6 publications

(1 citation statement)

References 10 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These include H1- and H2-receptor antagonists and disodium cromoglycate. PUVA or UVA1 therapy may reduce mast cell numbers and alleviate symptoms for several months [6]. Topical application of highly potent corticosteroids under occlusion has been used successfully in adult patients with urticaria pigmentosa and in solitary mastocytoma in children.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of 25% Diluted Fluticasone Propionate 0.05% Cream as Wet-Wrap Treatment in Cutaneous Mastocytosis

Heide

Spek²,

Hollander³

et al. 2007

Dermatology

View full text Add to dashboard Cite

Background: Mastocytosis is a disorder that can be subdivided into two forms: cutaneous and systemic. Patients with cutaneous mastocytosis only may suffer from cosmetic problems. Topical steroid application has been shown to be effective in cases of limited skin lesions. Methods: A case-controlled pilot study was conducted during a 6-weeks treatment using diluted 25% fluticasone propionate 0.05% cream under wet-wrap occlusion in 5 adults and 6 children. Improvement was measured up to the 24th week after treatment using the SCORMA Index. Results: The results of this pilot study showed a partial but clear cosmetic improvement in 9 of the 11 patients. The mean SCORMA Index decreased after treatment from 38 to 26. Conclusion: 25% dilution of fluticasone propionate 0.05% cream under wet-wrap occlusion is an alternative treatment modality for alleviating the symptoms of cutaneous mastocytosis, but the improvement may be moderate and fall short of the patient’s expectations.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy of 25% Diluted Fluticasone Propionate 0.05% Cream as Wet-Wrap Treatment in Cutaneous Mastocytosis

Heide

Spek²,

Hollander³

et al. 2007

Dermatology

View full text Add to dashboard Cite

show abstract

Pediatric Mastocytosis: Recognition and Management

Schaffer

2021

Am J Clin Dermatol

View full text Add to dashboard Cite

Urticaria pigmentosa

Brockow

2004

Immunology and Allergy Clinics of North America

View full text Add to dashboard Cite

Urticaria pigmentosa (UP), resulting from the accumulation of excessive numbers of mast cells in the skin, is the most common form of cutaneous mastocytosis. Observations highlight the diversity of this disease. Clonal expansion of early hematopoietic progenitor cells carrying activating mutations in KIT seems to be the basis of adult-onset UP. New pathogenetic findings are leading to the development of new diagnostic surrogate markers of disease and therapeutic approaches targeting neoplastic mast cells. Promising strategies may arise from an increased understanding about the cause of mastocytosis and the signaling pathways initiated by kit activation.

show abstract

Mastocytoma: topical corticosteroid treatment

Cited by 6 publications

References 10 publications

Efficacy of 25% Diluted Fluticasone Propionate 0.05% Cream as Wet-Wrap Treatment in Cutaneous Mastocytosis

Efficacy of 25% Diluted Fluticasone Propionate 0.05% Cream as Wet-Wrap Treatment in Cutaneous Mastocytosis

Pediatric Mastocytosis: Recognition and Management

Urticaria pigmentosa

Contact Info

Product

Resources

About